[HTML][HTML] Mutant p53 as a target for cancer treatment
MJ Duffy, NC Synnott, J Crown - European journal of cancer, 2017 - Elsevier
Abstract TP53 (p53) is the single most frequently altered gene in human cancers, with
mutations being present in approximately 50% of all invasive tumours. However, in some of …
mutations being present in approximately 50% of all invasive tumours. However, in some of …
Molecular mechanisms of apoptosis and roles in cancer development and treatment
Programmed cell death (PCD) or apoptosis is a mechanism which is crucial for all
multicellular organisms to control cell proliferation and maintain tissue homeostasis as well …
multicellular organisms to control cell proliferation and maintain tissue homeostasis as well …
Epigenetic therapy for ovarian cancer: promise and progress
S Moufarrij, M Dandapani, E Arthofer, S Gomez… - Clinical …, 2019 - Springer
Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of
approximately 47%, a number that has remained constant over the past two decades. Early …
approximately 47%, a number that has remained constant over the past two decades. Early …
p53: protection against tumor growth beyond effects on cell cycle and apoptosis
X Wang, ER Simpson, KA Brown - Cancer research, 2015 - AACR
The tumor suppressor p53 has established functions in cancer. Specifically, it has been
shown to cause cell-cycle arrest and apoptosis in response to DNA damage. It is also one of …
shown to cause cell-cycle arrest and apoptosis in response to DNA damage. It is also one of …
TP 53 mutations in human cancer: database reassessment and prospects for the next decade
B Leroy, M Anderson, T Soussi - Human mutation, 2014 - Wiley Online Library
More than 50% of human tumors carry TP 53 gene mutations and in consequence more
than 45,000 somatic and germline mutations have been gathered in the UMD TP 53 …
than 45,000 somatic and germline mutations have been gathered in the UMD TP 53 …
A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials
E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …
Gambogic acid as a candidate for cancer therapy: a review
Y Liu, Y Chen, L Lin, H Li - International Journal of Nanomedicine, 2020 - Taylor & Francis
Gambogic acid (GA), a kind of dry resin secreted by the Garcinia hanburyi tree, is a natural
active ingredient with various biological activities, such as anti-cancer, anti-inflammatory …
active ingredient with various biological activities, such as anti-cancer, anti-inflammatory …
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
K Messaoudi, A Clavreul, F Lagarce - Drug discovery today, 2015 - Elsevier
Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …
Challenges of phototherapy for neonatal hyperbilirubinemia
J Wang, G Guo, A Li, WQ Cai… - Experimental and …, 2021 - spandidos-publications.com
Phototherapy is universally recognized as the first option for treating neonatal jaundice due
to its unparalleled efficiency and safety in reducing the high serum free bilirubin levels and …
to its unparalleled efficiency and safety in reducing the high serum free bilirubin levels and …
Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
Abstract Since Mdm2 (Mouse double minute 2) inhibitors show serious toxicity in clinic
studies, different approaches to achieve therapeutic reactivation of p53-mediated tumor …
studies, different approaches to achieve therapeutic reactivation of p53-mediated tumor …